AR002749A1 - Derivados de estiril bencimidazol y composicion farmaceutica que los comprende. - Google Patents

Derivados de estiril bencimidazol y composicion farmaceutica que los comprende.

Info

Publication number
AR002749A1
AR002749A1 ARP960102799A AR10279996A AR002749A1 AR 002749 A1 AR002749 A1 AR 002749A1 AR P960102799 A ARP960102799 A AR P960102799A AR 10279996 A AR10279996 A AR 10279996A AR 002749 A1 AR002749 A1 AR 002749A1
Authority
AR
Argentina
Prior art keywords
derivatives
pharmaceutical composition
carbon atoms
estiril
bencimidazole
Prior art date
Application number
ARP960102799A
Other languages
English (en)
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of AR002749A1 publication Critical patent/AR002749A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Un derivado de estiril bencimidazol que tiene la fórmula (I), en donde: R1 y R2 son hidrógeno, halógeno, alquilo de 1 a 6 átomos de carbono, alcoxi de1 a 6 átomos de carbono, nitro carboxilo, alcoxicarbonilo de 2 a 7 átomos de carbono o arilcarbonilo de 7 a 12 átomos de carbono;o la fórmula (II), en dondeR4 y R5 son H o alquilo de 1 a 6 átomos de carbono; o una sal farmacéutica del mismo. Estos derivados son útiles como inhibidores de la proliferación decélulas de músculo liso. Además, se da a conocer una composición farmacéutica que comprende a dichos derivados.
ARP960102799A 1995-06-06 1996-05-30 Derivados de estiril bencimidazol y composicion farmaceutica que los comprende. AR002749A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/468,271 US6444694B1 (en) 1995-06-06 1995-06-06 Styryl benzimidazole derivatives

Publications (1)

Publication Number Publication Date
AR002749A1 true AR002749A1 (es) 1998-04-29

Family

ID=23859136

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960102799A AR002749A1 (es) 1995-06-06 1996-05-30 Derivados de estiril bencimidazol y composicion farmaceutica que los comprende.

Country Status (19)

Country Link
US (1) US6444694B1 (es)
EP (1) EP0830345B1 (es)
JP (1) JPH11506753A (es)
KR (1) KR19990022266A (es)
CN (1) CN1192206A (es)
AR (1) AR002749A1 (es)
AT (1) ATE205196T1 (es)
AU (1) AU711965B2 (es)
BR (1) BR9609153A (es)
CA (1) CA2223585A1 (es)
DE (1) DE69615023T2 (es)
DK (1) DK0830345T3 (es)
ES (1) ES2162063T3 (es)
HU (2) HUP9900679A3 (es)
IL (1) IL118385A0 (es)
NZ (1) NZ309499A (es)
PT (1) PT830345E (es)
WO (1) WO1996039391A1 (es)
ZA (1) ZA964693B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
KR101320907B1 (ko) 2004-02-20 2013-10-22 베링거 인겔하임 인터내셔날 게엠베하 바이러스 폴리머라제 억제제
WO2007019674A1 (en) 2005-08-12 2007-02-22 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
ES2689484T3 (es) 2006-07-05 2018-11-14 Fibrotech Therapeutics Pty Ltd Compuestos terapéuticos
CN105153188B (zh) * 2009-10-22 2018-06-01 法博太科制药有限公司 抗纤维化剂的稠环类似物
US11014873B2 (en) 2017-02-03 2021-05-25 Certa Therapeutics Pty Ltd. Anti-fibrotic compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3575956A (en) * 1967-07-24 1971-04-20 Sterling Drug Inc 2-substituted-benz-x-azol-6-ylazo-aminonaphthalene compounds
DE1670908A1 (de) * 1967-08-16 1971-04-29 Hoechst Ag Neue Benzimidazolverbindungen,Verfahren zu ihrer Herstellung und ihre Verwendung als optische Aufhellungsmittel
FR2104717A1 (en) * 1970-09-28 1972-04-21 Dynachim Sarl Organophosphorus pesticides stabilised with benzimidazole derivs - - for controlling insects and internal parasites of animals
DE3505609A1 (de) 1985-02-19 1986-08-21 Merck Patent Gmbh, 6100 Darmstadt Benzimidazolyl-pyridazinone
US5196446A (en) 1990-04-16 1993-03-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Certain indole compounds which inhibit EGF receptor tyrosine kinase
WO1991016305A1 (en) 1990-04-16 1991-10-31 Rhone-Poulenc Rorer International (Holdings), Inc. Heterocyclicethenediyl compounds which inhibit egf receptor tyrosine kinase
DE4212748A1 (de) 1992-04-16 1993-10-21 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5387600A (en) 1992-07-30 1995-02-07 Fuji Photo Film Co., Ltd. Treating arteriosclerosis using benzimidazole compositions

Also Published As

Publication number Publication date
ATE205196T1 (de) 2001-09-15
ZA964693B (en) 1997-12-05
AU5968496A (en) 1996-12-24
EP0830345A1 (en) 1998-03-25
MX9709647A (es) 1998-07-31
JPH11506753A (ja) 1999-06-15
AU711965B2 (en) 1999-10-28
KR19990022266A (ko) 1999-03-25
ES2162063T3 (es) 2001-12-16
HUP9900679A3 (en) 2001-07-30
US6444694B1 (en) 2002-09-03
HUP9900679A2 (hu) 1999-09-28
BR9609153A (pt) 1999-05-04
DK0830345T3 (da) 2001-11-19
WO1996039391A1 (en) 1996-12-12
DE69615023D1 (de) 2001-10-11
NZ309499A (en) 2000-08-25
IL118385A0 (en) 1996-09-12
CN1192206A (zh) 1998-09-02
CA2223585A1 (en) 1996-12-12
PT830345E (pt) 2002-01-30
DE69615023T2 (de) 2002-06-06
EP0830345B1 (en) 2001-09-05
HUP9900914A2 (hu) 1999-07-28

Similar Documents

Publication Publication Date Title
EE03869B1 (et) Sulfiinhappe derivaadid, nende valmistamine ja kasutamine
ES2085876T3 (es) Derivado de bifenilmetano, su utilizacion y composiciones farmacologicas que contienen el mismo.
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
ES2043625T3 (es) Derivados de acido ariloxicarboxilico, su preparacion y empleo.
CR7387A (es) Nuevos compuestos heterociclicos activos como inhibidores de las beta- lactamasas
SV1998000008A (es) Inhibisores de sulfamida-metaloproteasa. ref. ran 4070\114
AR027059A1 (es) Bases de mannich indolicas, procedimiento para su preparacion, medicamentos que contienen estos compuestos y su uso para la preparacion de medicamentos
AR006390A1 (es) Derivados de lactama
ES2140961T3 (es) Nuevos derivados de 19-nor-pregneno.
PT1305286E (pt) Ciclopentanoindoles composicoes que contem os referidos compostos e metodos de tratamento
ES2164920T3 (es) Nuevos derivados heterociclicos y uso medicinal de los mismos.
CY1105721T1 (el) Δερματικοι αναισθητικοι παραγοντες
AR002749A1 (es) Derivados de estiril bencimidazol y composicion farmaceutica que los comprende.
ES2060818T3 (es) Derivados de indol, benzofurano y benzotiofeno sustituidos como inhibidores de la 5-lipooxigenasa.
ES2165586T3 (es) Derivados de isatina como inhibidores de acetilcolinesterasa y analgesicos.
AR003137A1 (es) Una composicion farmaceutica para tratar la leucemia
ATE262509T1 (de) Indolinderivate als lichtschutzmittel
DE69808099D1 (de) Substituierte 6-alkylphenanthridine
NO20010654D0 (no) Ny anvendelse av taxoidderivater
ES2165407T3 (es) Compuestos beta-carbolina inhibidores de tromboxano sintasa.
DK1305037T3 (da) Smertestillende medikament
AR004691A1 (es) Nuevos derivados de [3-alcoxi-fenoxi-)-etil]-dialquilamina, una composicion farmaceutica que los comprende, su uso como anestesicos locales y unprocedimiento para su preparacion
AR003128A1 (es) Derivados de bencimidazol 2-sustituidos y composicion farmaceutica que los comprende.
AR006084A1 (es) Aminofeniluracilos substituidos y empleo de los mismos para la lucha contra las plantas indeseables
PA8444901A1 (es) Derivados de 5-aroilnaftaleno como agentes anti-inflamatorios